Paraneoplastic Cerebellar Degeneration: Treatment and Work-up
Immediately initiate aggressive cancer screening with CT chest/abdomen/pelvis (or FDG-PET if CT is negative) while simultaneously starting immunotherapy with corticosteroids, plasma exchange, and/or IVIG, because time is critical—neuronal destruction is relentless and longstanding symptoms rarely improve.
Diagnostic Work-up Algorithm
Step 1: Confirm the Diagnosis
CSF analysis is mandatory unless contraindicated 1. Look for:
- Lymphocytic pleocytosis (typically 20-200 cells, can be higher)
- Elevated protein
- Elevated IgG index/synthesis rate
- Oligoclonal bands
- Rule out infectious causes (HSV, VZV PCR, bacterial/fungal cultures)
Antibody testing in BOTH serum and CSF 1:
Step 2: Aggressive Cancer Screening
Initial screening should include CT chest/abdomen/pelvis with contrast 1, as the most common associated malignancies are:
- Small cell lung cancer
- Gynecologic cancers (ovarian, uterine)
- Breast cancer
- Hodgkin lymphoma
- Testicular tumors
Critical caveats:
- CT has low sensitivity for early breast and testicular cancers 1
- Add mammogram and breast MRI for women 1
- Consider testicular ultrasound for men
- If initial CT is negative, proceed to FDG-PET/CT 3—this may identify occult nodal disease even when primary tumor is undetectable
- In some cases, empiric surgical exploration may be warranted when antibodies strongly suggest gynecologic malignancy but imaging is unrevealing 3
Treatment Algorithm
Immediate Actions (Do Not Delay)
The prognosis worsens dramatically with treatment delay—neuronal loss is irreversible 7, 5.
Tumor treatment is paramount 7, 5:
- Surgical resection when feasible
- Chemotherapy/radiation as indicated
- Tumor control offers the best chance of neurologic stabilization
Initiate immunotherapy immediately, even before tumor is identified:
First-line options (start within days of presentation):
- High-dose IV methylprednisolone (1g daily × 3-5 days) 6, 2
- Plasma exchange should be considered early to rapidly lower circulating antibodies 7, 5, 6, though evidence for benefit when used alone is limited
- IVIG (2g/kg divided over 2-5 days) 8, 3
Many experts combine these modalities rather than using monotherapy 6, 3.
Second-line Therapies for Refractory Cases
If no stabilization or improvement occurs within 2-4 weeks:
- Cyclophosphamide 7, 5
- Rituximab (particularly for anti-Ri cases) 5, 4
- Tacrolimus 7, 8
- Mycophenolate mofetil 7
Experimental/Salvage Therapy
Autologous hematopoietic stem cell transplantation (AHSCT) has shown promise in two recent cases with progressive PCD refractory to conventional immunotherapy 4. Both patients achieved meaningful neurologic improvement and functional independence. This should be considered in younger patients with progressive disease despite aggressive treatment, though this remains Class IV evidence.
Important Clinical Pitfalls
- Normal brain MRI does not exclude PCD 2—cerebellar atrophy may not be evident early in the disease course
- Seronegative cases occur and should still be treated aggressively if clinical suspicion is high 6
- Poor response to initial steroids should prompt immediate escalation rather than prolonged observation 2
- Anti-Yo antibody cases have particularly poor prognosis 3, with most patients remaining non-ambulatory despite treatment
- Younger patients (<40 years) with anti-Ma2 antibodies and testicular/germ cell tumors have better treatment response 5
- Tumor recurrence can occur without neurologic worsening if the autoimmune process has been adequately controlled 4
Prognosis Expectations
Be realistic with patients: neurologic recovery is limited once extensive neuronal loss has occurred 7, 5. The goal is stabilization and prevention of further deterioration rather than complete recovery, particularly in patients presenting after months of symptoms. Early intervention (within weeks of symptom onset) offers the only realistic chance of meaningful improvement.